Vismodegib-RT Regimen Achieves High Rate of Disease Control in Head and Neck BCC
More than 90% of patients with locally advanced basal cell carcinoma (BCC) of the head and neck achieved locoregional control (LRC) with vismodegib (Erivedge) and radiation therapy (RT), a small clinical trial showed. LRC at 1 year was 91% after vismodegib induction therapy followed by concurrent vismodegib and RT. The overall response rate was 63% […]
FDA Approves New First-Line Standard of Care in Bladder Cancer
Patients with locally advanced or metastatic bladder cancer have a permanent new first-line standard of care after the FDA granted full approval to the combination of enfortumab vedotin (Padcev) and pembrolizumab (Keytruda) regardless of cisplatin eligibility. The action finalized the approval process for the combination, which received accelerated approval earlier this year, at the time […]
Experts Quell Worries About Locally Acquired Malaria in the U.S.
Earlier this week, the CDC issued an alert on the first locally acquired malaria cases in the U.S. in 20 years. MedPage Today spoke with experts and physicians to determine how rare the cases are, whether there may be more, and what may have contributed to them. Within the last 2 months, four locally acquired […]
Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer
NEW YORK — An immunotherapy-chemoradiotherapy (CRT) combination did not boost progression-free survival (PFS) in untreated, locally advanced cervical cancer, according to CALLA trial findings. Newly diagnosed patients who received durvalumab (Imfinzi) plus standard CRT did not experience a statistically significant PFS improvement versus patients who received placebo plus CRT (hazard ratio 0.84, 95% CI 0.65-1.08, […]
CDC Rats Out First U.S. Transmission of Seoul Hantavirus
Two service workers in Washington, D.C. contracted Seoul hantavirus in what is believed to be the first locally transmitted cases of the virus on U.S. soil. Both patients presented with several days of chills, high fever, headache, diarrhea, and vomiting. Both had acute kidney injury and responded to supportive treatment, and were later discharged. Rats […]
Darolutamide Tied to Symptom Control in Non-Metastatic Prostate Cancer
Darolutamide (Nubeqa) was linked with a decrease in locally invasive procedures, as well as local urinary and bowel symptoms, in patients with nonmetastatic (nm) castration-resistant prostate cancer (CRPC), according to analysis of the ARAMIS trial. The drug, compared with placebo, was also associated with a delayed deterioration in patient quality of life (QoL) related to […]